Hans Klingemann
About Hans Klingemann
Hans Klingemann Title and Role
Hans Klingemann holds the position of Chief Science Officer – Cellular. In this role, he oversees scientific strategies and research activities related to cellular technologies. His leadership is pivotal in advancing innovations in the field of cellular therapies.
Hans Klingemann Education and Expertise
Hans Klingemann is extensively qualified, holding both a Doctor of Medicine (M.D.) and a Doctor of Philosophy (Ph.D.). His dual academic credentials underpin his expertise in medical and scientific research. This combination enables him to effectively bridge clinical practices with advanced cellular research.
Hans Klingemann's Work with NK-92 Cell Line
Hans Klingemann is credited with establishing the NK-92 cell line, a significant development in cellular therapy. The NK-92 cell line is known for its applications in immunotherapy, specifically in targeting and combating cancer cells. This groundbreaking contribution has had a substantial impact on advancements in cancer treatment and research.
Isolation of Natural Killer (NK) Cells by Hans Klingemann
Thirty years ago, Hans Klingemann isolated natural killer (NK) cells characterized by broader and higher cytotoxic activity compared to other NK cells. This pioneering work has provided a foundation for advancements in cancer immunotherapy, leveraging the enhanced cytotoxic capabilities of these NK cells to target and destroy malignant cells more effectively.